Nystatin Oral Suspension, USP, 100,000 units/mL, packaged in a) 2 fl.oz. (60mL) bottles (NDC 6668...
FDA Drug Recall #D-0869-2017 — Class III — May 17, 2017
Recall Summary
| Recall Number | D-0869-2017 |
| Classification | Class III — Low risk |
| Date Initiated | May 17, 2017 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | VistaPharm, Inc. |
| Location | Largo, FL |
| Product Type | Drugs |
| Quantity | 2,208,500 cups/18696 bottles |
Product Description
Nystatin Oral Suspension, USP, 100,000 units/mL, packaged in a) 2 fl.oz. (60mL) bottles (NDC 66689-008-02), and 500,000 units/5mL individual unit dose cup (NDC 66689-037-01) packaged in b) 50 count unit dose cups/case (NDC 66689-037-50) and c) 100 count unit dose cups/case (NDC 66689-037-99) Rx only, Manufactured by: VistaPharm, Largo, FL 33771.
Reason for Recall
Failed Impurities/Degradation Specifications: Presence of an impurity peak that exceeds approved specification.
Distribution Pattern
Nationwide in the US and Puerto Rico
Lot / Code Information
a) Lot #: 431300, Exp. 01/2018; b) Lot #: 434000, 432500, Exp. 07/2017;462200, Exp. 02/2018 c) Lot #: 443800, 445500, Exp. 09/2017; 460500, 461500, Exp. 01/2018.
Other Recalls from VistaPharm, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0018-2023 | Class II | Pyridostigmine Bromide Oral Solution, USP 60 mg... | Sep 30, 2022 |
| D-0376-2022 | Class II | Clobazam Oral Suspension 2.5 mg/mL, 120 mL bott... | Jan 7, 2022 |
| D-0019-2021 | Class III | NYSTATIN ORAL SUSPENSION, USP 100,000 units per... | Sep 25, 2020 |
| D-1377-2020 | Class III | Nystatin Oral Suspension, USP 500,000 units/5mL... | Jun 23, 2020 |
| D-1378-2020 | Class III | Nystatin Oral Suspension, USP 100,000 units per... | Jun 23, 2020 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.